• Group revenue up 65% to $11.1m, driven by strong sales growth in ANZ Retail and China CBEC
• Adjusted EBITDA improved by 59% to -$1.3m
• Inventory reduced by 27% since June 2024, optimizing working capital

Nuchev Ltd has reported its half-year results for the six months ended 31 December 2024. The company delivered strong revenue growth, with group revenue up 65% to $11.1m, reflecting strong sales in ANZ Retail and China CBEC for Oli6® Nutritionals, as well as $4.8m in incremental sales from the acquisition of bWellness. Adjusted EBITDA improved by 59% to -$1.3m, driven by the integration of the higher-margin bWellness business and synergies in general and administrative expenses. The company also demonstrated a continued focus on supply chain optimization, reducing inventory holdings by 27% since 30 June 2024 and delivering working capital benefits. Key priorities for H2 FY25 include leveraging the distribution agreement with H&S Group to accelerate growth in China CBEC and South-East Asia, continued sales growth through bWellness, further organic growth in ANZ Retail, new product development, and unlocking supply chain efficiencies.

The company remains focused on driving the business to achieve breakeven, with key priorities including leveraging the H&S Group distribution agreement to accelerate growth in China CBEC and South-East Asia, continued sales growth through bWellness, further organic growth in ANZ Retail, new product development, and unlocking supply chain efficiencies.